ArticleBioengineering (Basel, Switzerland)2024
Enhanced Diabetes Detection and Blood Glucose Prediction Using TinyML-Integrated E-Nose and Breath Analysis: A Novel Approach Combining Synthetic and Real-World Data.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial Intelligence for Blood Glucose Level Prediction in Type 1 Diabetes: Methods, Evaluation, and Emerging Advances.Sensors (Basel, Switzerland) · 2026Review
- Machine Learning-Driven E-Nose-Based Diabetes Detection: Sensor Selection and Feature Reduction Study.Sensors (Basel, Switzerland) · 2025Article
- Electronic-Nose Technology for Lung Cancer Detection: A Non-Invasive Diagnostic Revolution.Lung · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus, a chronic condition affecting millions worldwide, necessitates continuous monitoring of blood glucose level (BGL). The increasing prevalence of diabetes has driven the development of non-invasive methods, such as electronic noses (e-noses), for analyzing exhaled breath and detecting biomarkers in volatile organic compounds (VOCs). Effective machine learning models require extensive patient data to ensure accurate BGL predictions, but previous studies have been limited by small sample sizes. This study addresses this limitation by employing conditional generative adversarial networks (CTGAN) to generate synthetic data from real-world tests involving 29 healthy and 29 diabetic participants, resulting in over 14,000 new synthetic samples. These data were used to validate machine learning models for diabetes detection and BGL prediction, integrated into a Tiny Machine Learning (TinyML) e-nose system for real-time analysis. The proposed models achieved an 86% accuracy in BGL identification using LightGBM (Light Gradient Boosting Machine) and a 94.14% accuracy in diabetes detection using Random Forest. These results demonstrate the efficacy of enhancing machine learning models with both real and synthetic data, particularly in non-invasive systems integrating e-noses with TinyML. This study signifies a major advancement in non-invasive diabetes monitoring, underscoring the transformative potential of TinyML-powered e-nose systems in healthcare applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.